Pettigrew Morgan F, Abreu Andres A, Al Abbas Amr I, Karalis John D, Alterio Rodrigo E, Ethun Cecilia G, Polanco Patricio M, Mansour John C, Yopp Adam C, Zeh Herbert J, Wang Sam C, Porembka Matthew R
Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Ann Surg Oncol. 2025 Mar 30. doi: 10.1245/s10434-025-17232-w.
Delay in gastric cancer diagnosis is associated with inferior outcomes. The effects of pre-existing mental health disorders (MHDs) on delays in gastric cancer diagnosis and treatment disparities are not well-understood. In this study, we evaluated the impact of MHDs on time to gastric cancer diagnosis and receipt of guideline-concordant treatment.
We performed a retrospective review of patients diagnosed with gastric adenocarcinoma between 2015 and 2022. Patients with pre-existing diagnoses of mood, affective, and substance use disorders were classified as having an MHD. Univariable and multivariable regression were used to analyze the association between MHDs and delay in diagnosis. The association between MHD and receipt of guideline-concordant care was also evaluated.
Overall, 460 patients diagnosed with gastric cancer were included in the analytic group. Seventy patients (15%) had an MHD prior to their cancer diagnosis, of whom 34 (49%) experienced a delay in diagnosis, compared with 109 (28%) without an MHD. On multivariable regression, patients with an MHD were more likely to experience a delay in diagnosis (odds ratio [OR] 2.84, 95% confidence interval [CI] 1.58-5.11; p < 0.001) and have more than one visit to a provider prior to diagnosis (OR 2.71, 95% CI 1.37-5.37; p = 0.004). Patients with an MHD were also less likely to receive guideline-concordant care for their gastric cancer (OR 0.29, 95% CI 0.12-0.67; p = 0.004).
MHD is a patient-level factor that negatively impacts gastric cancer care. Addressing provider knowledge gaps and increasing efforts to counter the social stigma and implicit bias associated with MHD may improve the time to diagnosis and receipt of guideline-concordant care in this at-risk population.
胃癌诊断延迟与较差的预后相关。既往存在的心理健康障碍(MHDs)对胃癌诊断延迟和治疗差异的影响尚未得到充分理解。在本研究中,我们评估了MHDs对胃癌诊断时间和接受符合指南治疗的影响。
我们对2015年至2022年间被诊断为胃腺癌的患者进行了回顾性研究。既往被诊断为情绪、情感和物质使用障碍的患者被归类为患有MHD。采用单变量和多变量回归分析MHDs与诊断延迟之间的关联。还评估了MHD与接受符合指南治疗之间的关联。
总体而言,460例被诊断为胃癌的患者纳入分析组。70例(15%)患者在癌症诊断前患有MHD,其中34例(49%)经历了诊断延迟,而无MHD的患者为109例(28%)。在多变量回归分析中,患有MHD的患者更有可能经历诊断延迟(优势比[OR] 2.84,95%置信区间[CI] 1.58 - 5.11;p < 0.001),并且在诊断前看诊次数超过一次(OR 2.71,95% CI 1.37 - 5.37;p = 0.004)。患有MHD的患者接受胃癌符合指南治疗的可能性也较小(OR 0.29,95% CI 0.12 - 0.67;p = 0.004)。
MHD是一个对胃癌治疗产生负面影响的患者层面因素。解决医疗服务提供者的知识差距,并加大力度消除与MHD相关的社会耻辱感和隐性偏见,可能会改善这一高危人群的诊断时间和接受符合指南治疗的情况。